Pacira BioSciences, Inc. — Director's Dealing 2021

Jun 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pacira BioSciences, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2021-06-09

Reporting Person: Riker Lauren Bullaro (Vice President, Finance)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-09	Common Stock	A	2600	$0.00	Acquired	14734	Direct
2021-06-11	Common Stock	S	2003	$59.85	Disposed	12731	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-09	Stock Option (Right to Buy)	$60.96	A	6500	Acquired	2031-06-09	Common Stock (6500)	Direct

Footnotes

F1: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.820 to $59.845, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth this footnote.

F3: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.